HHS Announces Department-Wide Clinical Trial Initiative - Summary - MDSpire

HHS Announces Department-Wide Clinical Trial Initiative

Agency-wide effort targets US clinical trial timelines, enrollment, and regulatory barriers.

  • By

  • Conexiant News Staff

  • June 23, 2026

  • 7 min

Share

Objective:

To strengthen the US position in clinical research and accelerate the development of new treatments, as announced by the US Department of Health and Human Services.

Approach:
    Key Findings:
    • China's share of global Phase 1 trials surpassed that of the US for the first time in 2021.
    • The average time for a US sponsor's IND submission is approximately 380 days.
    • Fewer than 5% of cancer patients receive treatment through clinical trials despite high willingness to participate.
    Interpretation:

    The initiative aims to address delays in clinical trial processes and enhance the US's competitive edge in clinical research.

    Limitations:
    • The roadmap does not provide specific timelines for implementation of proposed changes.
    • Potential challenges in aligning multiple HHS agencies and stakeholders.
    Conclusion:

    The initiative represents a comprehensive effort to modernize and expedite clinical trial processes in the US.

    Sources:

Original Source(s)

HHS Announces Department-Wide Clinical Trial Initiative

  • by Conexiant News Staff

  • June 23, 2026

Related Content

How Many US Clinicians Come From Banned Countries?

Counties with at least one clinician from a banned country were more likely to be designated primary care shortage areas.

Early Neurodevelopmental Outcomes in Pediatric Congenital Heart Disease

In a multicenter registry study, genetic diagnoses were associated with substantially lower cognitive, language, and motor scores; while birth weight, surgical timing, hospitalization burden, and caregiver education were also associated with outcomes.

Fertility Issues May Be Linked to Autism

In a nationwide US cohort, parental subfecundity was associated with higher odds of autism spectrum disorder and modest increases in behavioral symptoms, while in vitro fertilization showed no statistically significant associations with neurodevelopmental outcomes.